JP6582039B2 - 腫瘍血管を選択的に破壊する金属フラーレン単結晶ナノ粒子による腫瘍治療方法 - Google Patents
腫瘍血管を選択的に破壊する金属フラーレン単結晶ナノ粒子による腫瘍治療方法 Download PDFInfo
- Publication number
- JP6582039B2 JP6582039B2 JP2017503020A JP2017503020A JP6582039B2 JP 6582039 B2 JP6582039 B2 JP 6582039B2 JP 2017503020 A JP2017503020 A JP 2017503020A JP 2017503020 A JP2017503020 A JP 2017503020A JP 6582039 B2 JP6582039 B2 JP 6582039B2
- Authority
- JP
- Japan
- Prior art keywords
- single crystal
- cancer
- tumor
- metal fullerene
- crystal nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 134
- 229910052751 metal Inorganic materials 0.000 title claims description 101
- 239000002184 metal Substances 0.000 title claims description 101
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 title claims description 99
- 229910003472 fullerene Inorganic materials 0.000 title claims description 96
- 239000002105 nanoparticle Substances 0.000 title claims description 92
- 239000013078 crystal Substances 0.000 title claims description 88
- 210000004204 blood vessel Anatomy 0.000 title claims description 58
- 238000000034 method Methods 0.000 title description 30
- 238000011282 treatment Methods 0.000 title description 27
- 201000011510 cancer Diseases 0.000 claims description 15
- 230000007704 transition Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 210000002889 endothelial cell Anatomy 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 2
- 150000002602 lanthanoids Chemical class 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 208000037830 nasal cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229910052706 scandium Inorganic materials 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 229910052765 Lutetium Inorganic materials 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000004477 skin sarcoma Diseases 0.000 claims 1
- 239000004066 vascular targeting agent Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 239000002086 nanomaterial Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000005747 tumor angiogenesis Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002715 modification method Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002324 minimally invasive surgery Methods 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 108090000765 processed proteins & peptides Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010049765 Bradyarrhythmia Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0487—Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
Description
Claims (5)
- 腫瘍を治療するための薬剤セットであって、
前記薬剤セットは、腫瘍血管破壊剤の調製に用いる金属フラーレン単結晶ナノ粒子と、該金属フラーレン単結晶ナノ粒子に含まれる金属フラーレンに適合した放射エネルギー源を供給する装置と、からなり、
前記金属フラーレン単結晶ナノ粒子は、表面に負電荷を有する水溶性の金属フラーレン単結晶ナノ粒子であり、
前記単結晶ナノ粒子の粒子サイズは、50〜250ナノメートルの範囲にあり、
前記単結晶ナノ粒子の相転移温度は、40〜90℃の範囲にあり、
前記ナノ粒子は、剛性を有し、腫瘍の血管壁の細孔を通過する際に嵌まり込み、
さらに、前記ナノ粒子は、外部放射エネルギーを吸収し、該放射エネルギーを熱エネルギーに変換し、同時に、該熱エネルギーを蓄積することができ、その際に、前記金属フラーレン単結晶ナノ粒子の体積が、相転移によって急速に膨張し、それによって、腫瘍血管の内皮細胞の形態、構造、機能のいずれかに変化を引き起こし、
前記放射エネルギー源は高周波であることを特徴とする腫瘍を治療するための薬剤セット。 - 前記金属フラーレン単結晶ナノ粒子における金属フラーレンは、M@C2n、M2@C2n、MA@C2n、M3N@C2n、M2C2@C2n、M2S@C2n、M2O@C2n、MxA3−xN@C2n、の少なくとも1種から選択されることを特徴とする請求項1に記載の薬剤セット。
ただし、MおよびAはともに金属元素を表し、MおよびAはともに、Sc、Yおよびランタナイド金属元素のいずれか1つより選択され、30≦n≦60、0≦x≦3である。 - 前記金属フラーレン単結晶ナノ粒子は、Gd@C82(OH)xのようなヒドロキシル基で修飾された単結晶ナノ粒子、Gd@C82(OH)x(NH2)yのようなヒドロキシル基とアミノ基で同時に修飾された単結晶ナノ粒子、Gd@C60(OH)xC60、Gd@C60(COOH)xのようなC60系の金属フラーレン単結晶ナノ粒子、Gd3N@C80(OH)x(NH2)y、Gd@C82(OH)x(COOH)y、Lu3N@C80(OH)x(NH2)yのような他の金属フラーレン単結晶ナノ粒子のいずれかであることを特徴とする請求項1から2のいずれか1項に記載の薬剤セット。
ただし、xは全て10〜30の間の整数を表し、yは全て0〜20の間の整数を表している。 - 前記腫瘍は、固形腫瘍であることを特徴とする請求項1から3のいずれか1項に記載の薬剤セット。
- 前記固形腫瘍は、肝臓癌、肺癌、結直腸癌、腎臓癌、膵臓癌、骨癌、乳癌、卵巣癌、前立腺癌、食道癌、胃癌、口腔癌、鼻癌、喉頭癌、胆管癌、子宮頸癌、子宮癌、精巣癌、髄膜腫、皮膚癌、黒色腫、肉腫を含むことを特徴とする請求項4に記載の薬剤セット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/000722 WO2016015172A1 (zh) | 2014-07-29 | 2014-07-29 | 一种通过纳米材料和外加辐射源实现肿瘤血管阻断的肿瘤治疗方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017521454A JP2017521454A (ja) | 2017-08-03 |
JP6582039B2 true JP6582039B2 (ja) | 2019-09-25 |
Family
ID=55216545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017503020A Active JP6582039B2 (ja) | 2014-07-29 | 2014-07-29 | 腫瘍血管を選択的に破壊する金属フラーレン単結晶ナノ粒子による腫瘍治療方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20170216436A1 (ja) |
EP (1) | EP3130351A4 (ja) |
JP (1) | JP6582039B2 (ja) |
AU (1) | AU2014402251B2 (ja) |
CA (1) | CA2940611C (ja) |
WO (1) | WO2016015172A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108926721B (zh) * | 2017-05-27 | 2021-05-04 | 深圳大学 | 一种聚多巴胺-金属富勒烯载药复合纳米粒子的制备方法及其用途 |
CN108217626B (zh) * | 2017-12-29 | 2019-11-22 | 华中科技大学 | 一种实现内包金属富勒烯快速分离的方法 |
CN109402052B (zh) * | 2018-10-15 | 2022-02-22 | 宁波美晶医疗技术有限公司 | 一种用于捕获血液中外泌体的磁性纳米颗粒的制备方法及其应用 |
CN109691989B (zh) * | 2018-11-28 | 2021-10-01 | 武汉高德智感科技有限公司 | 一种基于红外人脸检测技术的人体温度测量方法 |
CN113548656B (zh) * | 2020-06-16 | 2023-02-21 | 哈尔滨成程生命与物质研究所 | 一种具有抗癌生物活性的碳点及制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739562A (zh) * | 2005-09-19 | 2006-03-01 | 中国科学院高能物理研究所 | 金属富勒醇在抑制肿瘤生长中的应用 |
CN1935812B (zh) * | 2005-09-19 | 2010-04-21 | 中国科学院高能物理研究所 | 金属富勒醇及其在制备抑制肿瘤生长药物中的应用 |
WO2008140576A2 (en) * | 2006-12-05 | 2008-11-20 | University Of Florida Research Foundation, Inc. | Systems and methods based on radiation induced heating or ignition of functionalized fullerenes |
WO2009091597A2 (en) * | 2008-01-16 | 2009-07-23 | Nanospectra Biosciences, Inc. | Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy |
CN103316341A (zh) * | 2013-06-26 | 2013-09-25 | 郑州大学 | 富勒烯-纳米金复合材料及其制备方法与应用 |
CN104127873B (zh) * | 2014-07-29 | 2016-05-18 | 北京福纳康生物技术有限公司 | 一种由纳米材料和外加辐射源组成的实现肿瘤血管阻断的肿瘤治疗药物 |
CN104127872B (zh) * | 2014-07-29 | 2016-05-25 | 北京福纳康生物技术有限公司 | 金属富勒烯单晶纳米颗粒在制备特异性肿瘤血管阻断剂中的应用 |
-
2014
- 2014-07-29 CA CA2940611A patent/CA2940611C/en active Active
- 2014-07-29 US US15/329,116 patent/US20170216436A1/en not_active Abandoned
- 2014-07-29 JP JP2017503020A patent/JP6582039B2/ja active Active
- 2014-07-29 EP EP14898405.7A patent/EP3130351A4/en not_active Withdrawn
- 2014-07-29 AU AU2014402251A patent/AU2014402251B2/en not_active Ceased
- 2014-07-29 WO PCT/CN2014/000722 patent/WO2016015172A1/zh active Application Filing
-
2020
- 2020-04-01 US US16/837,953 patent/US20200246458A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014402251B2 (en) | 2019-11-21 |
US20170216436A1 (en) | 2017-08-03 |
CA2940611C (en) | 2020-12-01 |
EP3130351A4 (en) | 2017-12-13 |
WO2016015172A8 (zh) | 2016-07-28 |
EP3130351A1 (en) | 2017-02-15 |
US20200246458A1 (en) | 2020-08-06 |
AU2014402251A1 (en) | 2017-02-23 |
WO2016015172A9 (zh) | 2016-06-30 |
WO2016015172A1 (zh) | 2016-02-04 |
CA2940611A1 (en) | 2016-02-04 |
JP2017521454A (ja) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Canavese et al. | Nanoparticle-assisted ultrasound: A special focus on sonodynamic therapy against cancer | |
Tang et al. | In vivo targeted, responsive, and synergistic cancer nanotheranostics by magnetic resonance imaging-guided synergistic high-intensity focused ultrasound ablation and chemotherapy | |
US20200246458A1 (en) | Method for treating cancer based on metallofullerene monocrystalline nanoparticles that specifically disrupt tumor blood vessels | |
You et al. | Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy | |
Sun et al. | Physical triggering strategies for drug delivery | |
Sun et al. | Superparamagnetic PLGA-iron oxide microcapsules for dual-modality US/MR imaging and high intensity focused US breast cancer ablation | |
Zheng et al. | Biocompatible nanomotors as active diagnostic imaging agents for enhanced magnetic resonance imaging of tumor tissues in vivo | |
Zhao et al. | Phase-shifted PFH@ PLGA/Fe3O4 nanocapsules for MRI/US imaging and photothermal therapy with near-infrared irradiation | |
You et al. | Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic therapy in prostate cancer through ultrasound-controlled in situ accumulation | |
Wen et al. | Microwave pumped high-efficient thermoacoustic tumor therapy with single wall carbon nanotubes | |
CN104127872A (zh) | 金属富勒烯单晶纳米颗粒在制备特异性肿瘤血管阻断剂中的应用 | |
KR20170043862A (ko) | 종양 진단 및 치료용 나노입자 | |
Ribeiro et al. | Nanomaterials in cancer: Reviewing the combination of hyperthermia and triggered chemotherapy | |
Tam et al. | Imaging intratumoral nanoparticle uptake after combining nanoembolization with various ablative therapies in hepatic VX2 rabbit tumors | |
Wang et al. | Eumelanin–Fe 3 O 4 hybrid nanoparticles for enhanced MR/PA imaging-assisted local photothermolysis | |
Li et al. | Ultrasound activated nanosensitizers for sonodynamic therapy and theranostics | |
Zhou et al. | Liposomes loading sodium chloride as effective thermo-seeds for microwave ablation of hepatocellular carcinoma | |
Liu et al. | Designing pH-triggered drug release iron oxide nanocomposites for MRI-guided photothermal-chemoembolization therapy of liver orthotopic cancer | |
Xu et al. | Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy | |
Ding et al. | Multifunction in One Nanoparticle for Anticancer Therapy: Bowl-Shaped Au@ PDA Yolk–Shell NPs | |
Chen et al. | Controlling dielectric loss of biodegradable black phosphorus nanosheets by iron-ion-modification for imaging-guided microwave thermoacoustic therapy | |
Jiang et al. | US/MR bimodal imaging-guided bio-targeting synergistic agent for tumor therapy | |
WO2016074334A1 (zh) | 一种利用微纳材料特异性破坏肿瘤血管实现肿瘤靶向治疗的方法 | |
KR101292939B1 (ko) | 엠알유도 고강도집속초음파 치료 및 진단용 인지질 나노입자 및 이의 제조방법 | |
Choi et al. | Synergistic agents for tumor-specific therapy mediated by focused ultrasound treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180907 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190607 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190731 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190814 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190902 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6582039 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |